Shares of KemPharm, Inc. (NASDAQ:KMPH) last traded at $3.20. The firm’s performance so far in this year is 8.47%. The 200-day simple moving average is -20.66%. It is considered a key indicator by market analysts and traders for determining the long-term trend. The price mark in a market that coincides with it is recognized as a key support when price moves above the 200-day SMA or resistance when stock price is below this level.
As per recent filings, KemPharm, Inc. (NASDAQ:KMPH) has an insider ownership of 12.70%.
KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States.
KemPharm, Inc. (NASDAQ:KMPH) has been storming Wall Street with promising press release. Recently, the firm reported that according to the March 2017 analysis commissioned by RetailMeNot and performed by Forrester Consulting, the firm’s mobile marketing solutions result in a 3-year, risk-adjusted ROI of 4.3x.
The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend. The market is in highly oversold territory. Beware of a trend reversal.
The Exponential Moving Average is a tool same as a simple moving average, with the only difference being a weighting factor used by EMA that exponentially declines from the recent data point. EMA analysis checks the averages for different period, including short term that is 5 days and 13 days, intermediate term for 20 days and long term of 50 days EMA. The bullish signals are received when they trade above trailing EMAs and below the prevailing price and vice versa. EMA signals include crossovers and EMA convergences The 5 day EMA 3.71 is higher than the last trade price suggesting a short term bearish pattern building up. Long term, the 50 day EMA 4.13 is also higher than the current trading price depicting a bearish trend overall..
The relative strength index can be marked as a momentum oscillator that is able to read the velocity and magnitude of equity price changes. The current RSI is 21.77 suggesting a bearish price action.
KemPharm, Inc. (NASDAQ:KMPH) is all set to post its earnings on May 10/a. As per Zack’s analyst ratings, KemPharm, Inc. (NASDAQ:KMPH) presently has an average brokerage rating of . On a scale of 1 – 5, a rating of 2 or 1 would indicate a buy, and a 4 or 5 rating would signify a sell while a rating of 3 indicates a hold.
As such, while we consider KemPharm, Inc. (NASDAQ:KMPH) represents a convincing growth story exposed to different attractive markets, it would be enticing to see what it brings for long-term investors.